Day One Biopharmaceuticals’ (DAWN) “Buy” Rating Reiterated at Needham & Company LLC
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $33.00 price objective on the stock. Needham & Company LLC’s price target indicates a potential upside of […]
More Stories
Little Brother, John Cena’s Latest Movie Release Date, Cast, and Trailer
Netflix’s recent and upcoming film, Little Brother, is grabbing the attention of both comedy movie lovers and WWE fans because...
Judge Rules Virginia Redistricting Referendum Unconstitutional
By Jill McLaughlin A Virginia judge ruled on April 22 that the state’s redistricting referendum approved by voters a day earlier...
US Land Prices Climb 77 Percent Since Pandemic as Inventory Remains Low: Report
By Mary Prenon Land prices across the United States over the last decade seem to be following the path of...
German Airline Lufthansa to Cut 20,000 Flights to Save Jet Fuel
By Victoria Friedman German airline Lufthansa announced on April 21 that 20,000 short-haul flights would be canceled this summer due...
Duffy Seeking $10 Billion From Congress to Revamp Air Traffic Control System
By Aldgra Fredly U.S. Transportation Secretary Sean Duffy said on April 21 the department requires $10 billion in additional funding...
Iran Attacks 2 Container Ships After Trump Extends Ceasefire
By Tom Ozimek Iranian forces fired on two commercial vessels near the Strait of Hormuz on April 22, UK maritime...